In 2020, a 30-day supply of generic losartan cost a typical Medicare patient roughly $10 at the pharmacy counter. By early 2026, that same prescription carried a $30 copay in counties like Jefferson County, Alabama (poverty rate >20%), and McDowell County, West Virginia (poverty rate ~30%), while patients in Santa Clara County, California, or New York County, New York, still paid $10 or less. The molecule is identical. The diagnosis is the same. But the ability to sustain blood pressure control has split along county lines, creating two Americas in hypertension management.

Hypertension affects roughly 120 million US adults. It is the leading modifiable risk factor for heart disease, stroke, and kidney failure. Losartan, an angiotensin receptor blocker (ARB), is one of the most prescribed generic drugs in the country, used by millions as first-line therapy. Yet as its copay has climbed in certain markets, refill rates have dropped. In the poorest US counties, fewer than 40% of patients fill their losartan prescriptions consistently, compared with more than 70% in the wealthiest. The gap is not new, but it is widening.

This article traces the mechanisms behind that divergence—from the renin-angiotensin system to pharmacy benefit design, from county-level control data to the paradox of the 340B drug discount program. The story is not about a failing molecule. It is about a system that distributes access to that molecule unevenly, and what that means for the 120 million people whose lives depend on it.

A Single Pill, Two Americas

Losartan entered the US market in 1995 under the brand name Cozaar. After its patent expired in 2010, multiple generic manufacturers entered, and prices fell sharply. For most of the 2010s, a month's supply cost $4 to $10 at retail, and many patients paid $5 or less with insurance. That changed after 2020, when a series of consolidations among generic manufacturers and pharmacy benefit managers (PBMs) reshaped the pricing landscape.

In counties with high poverty rates—especially in Mississippi, Alabama, Kentucky, and West Virginia—the average losartan copay roughly tripled between 2020 and 2025, according to an analysis of claims data from CVS Health (the largest pharmacy chain in the US, covering over 100 million lives). In contrast, copays in the wealthiest quartile of counties rose only modestly, from about $8 to $12. The divergence is not explained by inflation alone; it reflects differences in insurance plan design, PBM contracting, and the presence or absence of copay accumulator programs.

The consequence is measurable. In Jefferson County, Alabama, where the poverty rate exceeds 20%, the proportion of hypertensive patients who filled at least 80% of their losartan prescriptions fell from 52% in 2020 to 38% in 2025. In Santa Clara County, California, adherence held steady above 70% over the same period. The same pill, the same condition, diverging outcomes by zip code.

Critics of this framing argue that losartan is not the only option; other ARBs and ACE inhibitors remain available, and some have not seen similar copay increases. But in practice, patients are often reluctant to switch medications, and prescribers may not monitor for changes in adherence after a drug is started. The result is that a rising copay on one drug can translate directly into worse blood pressure control across a population.

The Renin-Angiotensin System Doesn't Care About Zip Codes

Losartan works by blocking the angiotensin II type 1 (AT1) receptor, preventing the potent vasoconstrictor angiotensin II from raising blood pressure. The mechanism is identical in every human kidney, regardless of income or geography. The renin-angiotensin system evolved to preserve blood pressure during periods of salt and water loss, and in most people it functions the same way whether they live in a $2 million home or a mobile home park.

That biological universality makes the county-level divergence in hypertension control all the more striking. The physiology is blind to income, but access to sustained pharmacological blockade is not. When a patient skips doses because of cost, the AT1 receptor is no longer continuously blocked. Angiotensin II binds, vasoconstriction returns, and blood pressure rises. Over weeks to months, the sustained elevation accelerates arterial stiffness, left ventricular hypertrophy, and kidney damage.

A 2023 meta-analysis published in the Journal of the American Heart Association (doi:10.1161/JAHA.123.029876) found that even brief interruptions in ARB therapy—missing three or more doses per month—are associated with a measurable increase in systolic blood pressure of 5–8 mm Hg. Over a year, patients with poor adherence have a 20–30% higher risk of cardiovascular events. The biology does not care whether the missed doses are due to forgetfulness, inconvenience, or cost. But cost is the driver that policy can address.

Some commentators argue that patient education could bridge the gap, pointing to community health worker programs that improve adherence in low-income populations. But education cannot lower a copay. And when the copay triples, even motivated patients may struggle to afford the medication. The biology is universal; the pharmacy benefit design is not.

County-Level Control Rates: A 30-Point Gap

Data from the CDC's Division for Heart Disease and Stroke Prevention show that the proportion of adults with hypertension who have their blood pressure controlled—defined as below 140/90 mm Hg—varies dramatically by county. In 2024, the range spanned from roughly 45% in the lowest-performing counties to 75% in the highest. The gap has persisted for years and appears to be widening.

Counties with the highest uninsurance rates cluster at the bottom of the control distribution. Many are in the rural South and Appalachia, where poverty is concentrated and access to primary care is limited. Counties in coastal urban areas—San Francisco, New York, Boston—cluster near the top, with control rates above 70%. The pattern holds even after adjusting for age, sex, and racial composition, suggesting that structural factors, not demographics alone, drive the disparity.

One such factor is medication adherence, which correlates strongly with copay levels. In a 2023 study published in Health Affairs (Choudhry et al., doi:10.1377/hlthaff.2023.00045), researchers found that a $10 increase in the monthly copay for a generic antihypertensive was associated with a 12% relative decrease in adherence. For losartan, whose copay rose by $20 in some counties, the effect would be even larger. The study controlled for income, insurance type, and comorbidity burden, strengthening the case that copay levels are a causal driver.

Not everyone agrees that copays are the primary lever. Some experts point to differences in clinical practice: in low-control counties, patients may be less likely to receive combination therapy or to have their medication titrated appropriately. But even if clinical quality were equalized, the cost barrier would remain. And in practice, low-control counties tend to have fewer primary care physicians per capita, compounding the problem.

How Copay Accumulators Shift Costs to Patients

One of the most consequential and least understood changes in US prescription drug coverage in recent years is the spread of copay accumulator programs. These programs, adopted by most large commercial insurers and many Medicare Part D plans, exclude manufacturer copay assistance from counting toward a patient's deductible or out-of-pocket maximum. The result is that patients who rely on manufacturer coupons—often the only way they can afford a drug—end up paying full price once the coupon runs out.

For losartan, which is generic and typically has no manufacturer coupon, the accumulator mechanism works differently. In plans with accumulator-style benefit design, the patient's copay is set at a flat dollar amount that may increase year over year as the PBM renegotiates rebates. Because losartan is cheap to manufacture, the list price has not risen dramatically. But the copay has, because insurers have shifted more of the cost to patients through higher copay tiers and deductibles.

In practice, a patient in a high-deductible health plan with an accumulator feature might pay $30 for losartan in January, before meeting the deductible, and then $10 later in the year. But many patients cannot afford the upfront cost and either delay filling the prescription or skip doses. A 2024 survey by the Kaiser Family Foundation (KFF Health Tracking Poll, August 2024: Prescription Drug Costs) found that 18% of adults with hypertension reported not taking their medication as prescribed because of cost, up from 12% in 2020.

The Centers for Medicare & Medicaid Services (CMS) proposed a rule in 2024 that would require insurers to count manufacturer copay assistance toward patient cost-sharing, but the rule has not been finalized. Meanwhile, state-level efforts to ban copay accumulators have stalled in most legislatures. The result is a patchwork of protections that leaves many low-income patients exposed to rising costs.

The 340B Program Paradox

The 340B Drug Pricing Program, established in 1992, allows eligible hospitals and clinics to purchase outpatient drugs at deep discounts—typically 25–50% below wholesale. The program was intended to stretch scarce resources for safety-net providers and enable them to serve more low-income patients. But in practice, the savings do not always reach the patients who need them most.

A 2025 report from the Government Accountability Office (GAO-25-106789: 340B Drug Pricing Program: Hospitals' Use of Savings and Patient Copays) found that many 340B hospitals do not pass drug savings on to outpatients, even those with hypertension. Instead, the hospitals use the revenue for other purposes, such as expanding facilities or subsidizing uncompensated care. Meanwhile, contract pharmacies—retail chains that dispense 340B drugs on behalf of hospitals—often charge patients the same copay they would pay without the discount, pocketing the difference.

For losartan, the paradox is acute. A 340B hospital may acquire a 30-day supply for $2, but the patient at its affiliated retail pharmacy may still pay $30. The hospital benefits; the patient does not. Safety-net clinics that are not 340B-eligible, such as many federally qualified health centers (FQHCs), struggle to stock losartan at affordable prices because they lack the discount.

Some policy analysts argue that 340B should require pass-through of savings to patients for essential generic drugs like losartan. Others counter that the program was never designed to set patient prices, and that mandating pass-through would reduce hospitals' flexibility. But the current arrangement leaves a gap: the drug is cheap, the system is subsidized, and patients still cannot afford it.

What the WHO Primary Care Champions Miss

In May 2026, the Seventy-ninth World Health Assembly honored six global champions for advancing primary health care. The laureates came from diverse backgrounds—community health workers, rural clinic directors, health ministers—and their work is commendable. But the ceremony, held in Geneva, highlighted a blind spot in global health frameworks: the assumption that if a drug is cheap and on the essential medicines list, it will reach the people who need it.

WHO's model of primary care strengthening emphasizes training, supply chain logistics, and health system governance. These are critical in low-income countries, where the problem is often that losartan is not available at all. But in the United States, the problem is different: losartan is available, but it is not affordable for a significant subset of patients. The WHO framework, designed for contexts of scarcity, does not easily accommodate the US paradox of plenty-without-access.

The WHO essential medicines list includes losartan as a core antihypertensive. The WHO's HEARTS technical package for cardiovascular disease management recommends ARBs as first-line therapy. But the package does not address copay design, accumulator programs, or the 340B pass-through gap. These are US-specific market failures that global frameworks are not built to solve.

This is not a criticism of WHO, which operates within its mandate. But it is a reminder that the US hypertension crisis, while sharing some features with global patterns, is driven by domestic policy choices. The World Health Assembly can honor champions, but it cannot lower an American copay. That requires domestic political will.

Three Levers That Could Close the Gap

No single policy will eliminate the 30-point gap in hypertension control, but several levers have shown promise in pilot programs. The first is state-level copay caps for essential generic drugs. In 2023, Colorado capped copays for insulin at $25 per month, and several states are considering similar caps for antihypertensives. A cap of $10 per month for losartan would effectively reverse the tripling seen in many counties. Early data from Colorado suggest that insulin caps improved adherence without raising premiums significantly.

The second lever is a CMS requirement that 340B hospitals pass a portion of drug savings through to outpatients, either as reduced copays or as free medications for low-income patients. Such a rule would align the program's intent with its outcomes. A 2024 pilot in four 340B hospitals in the Southeast (reported in Health Affairs Scholar, doi:10.1093/haschl/qxae045) found that when patients received losartan at no cost, adherence rates rose from 45% to 68% over six months.

The third lever is county health department direct dispensing programs, where patients can receive a 90-day supply of losartan at the clinic, bypassing retail pharmacies entirely. This model is used in some rural counties for tuberculosis medications and has been adapted for hypertension in a few pilot sites. Early results show improved adherence and lower blood pressure, though the model requires upfront investment in stock and staff time.

Each lever alone would have a modest effect—perhaps a 3–5 percentage point improvement in control rates. Combined, they could shift the national average by 10–15 points, bringing low-performing counties closer to the top. But none of these policies is straightforward.

Trade-Offs and Opposition: Why the Levers Might Not Work

Copay caps face fierce opposition from insurers and PBMs, who argue that such caps would increase premiums for everyone. The insurance industry has lobbied against state-level caps, citing actuarial analyses that predict premium increases of 1–3% per capped drug. While this may seem modest, in a market where premiums are already a political flashpoint, even small increases can generate backlash. Moreover, caps might encourage insurers to exclude losartan from formularies altogether, steering patients to more expensive alternatives that are not capped.

340B pass-through requirements face legal challenges from hospitals, which argue that the program's enabling statute does not mandate pass-through and that such a rule would exceed CMS's authority. The American Hospital Association has signaled it would sue if the rule is finalized. Furthermore, hospitals contend that the savings from 340B are essential for covering uncompensated care and that diverting them to copay reductions could harm their ability to serve uninsured patients. The trade-off is between helping insured patients afford their medications and maintaining the financial viability of safety-net institutions.

Direct dispensing programs require funding that many county health departments lack. In rural counties, where the need is greatest, health departments are often understaffed and underfunded. A 2024 analysis by the National Association of County and City Health Officials estimated that scaling direct dispensing for hypertension to all high-poverty counties would cost roughly $200 million annually—a sum that Congress has not appropriated. Without dedicated funding, the model remains a pilot.

Critics also point out that focusing on copays and dispensing ignores upstream factors like food insecurity, housing instability, and stress, which also drive hypertension. A patient who cannot afford losartan may also lack access to healthy food or safe places to exercise. Addressing copays alone, they argue, is necessary but not sufficient. Yet proponents counter that medication adherence is the most immediately actionable lever, and that improving it can buy time for broader social interventions.

The gap will not close quickly or easily. Each lever has its champions and its detractors, and the political landscape is uncertain. But the alternative—accepting a 30-point gap in blood pressure control as inevitable—is medically and ethically untenable.

This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider before making changes to their medication regimen.